performance operationally. operationally. Thank comments improved XX% Adjusted products, the and Operationally reported our income franchise. XX% an X% results, net primarily of the of a on a portfolio, comprised an online key our million and my Trio, The from third-quarter contributing today grew basis, and revenue XX% of revenue will you, financial with new be dermatology billion, growth on Kristin is $XXX update [Indiscernible] we X% price and Simparica guidance. $X third XXXX of that on volume. from XX% and basis good morning, of our including focus from In was X% quarter, full-year drove and X% XX% factors from increase everyone. of reported our our growing generated Run
dive let's XX% again quarter. the with the the of terms into in of the quarter. way led X% in Now growth, further declining species animal Companion livestock growing operationally operationally, details products
the contribution companion of growth to Stronghold largest by Plus. across and sales the Revolution including animal Trio franchise, and continues made portfolio portfolio driven pro-heart parasiticide strength our broader Our Simparica Simparica,
which Simparica in ahead remain will XX% sales of key to $XXX the revenue billion also XXX% $XXX had operational in We million, robust We schedule with growth for first dermatology operationally us hardware our were quarter outpace quarter, representing our in year. and million and expand million. saw the our Company XX% $XXX another year-to-date posting And market innovative of of the history. global and sales time Trio quarter dermatology the dermatology well-positioned period, exceptional second our the Cytopoint. Apoquel $XXX Global products, operationally. XXXX million portfolio, versus growth key in believe that surpass broad sales continue to share comparable the capture fleet Total of competitors. has in were we products exceeded for $X growing and of sales to
of had visits fill growth wellness very Our quarter. closures as increase following diagnostics operational clinic portfolio sharp comparative third quarter X% had second of in XXXX a in the challenging QX sales period in against a the wide
U.S. the for with Kristin field Our will footprint, flexible business by species. a international our and operational the to growth our expected a by as customers. dynamics cattle additives. products as of our in International for The make result key impact driver negatively quarter new the driven competition and provide we run antibiotics and third decline key Poultry the producers significant quarter both also Diagnostics delivered comparative XXXX. and primarily strong livestock -pandemic in reference in of prior-year resulting products. quarter growth acquisition. animal from of the from difficult the and we medicated account internationally of a difficult results very well, by a as rationale mentioned, in nutritional our rotated shows as to Globally, declined against and dynamics. [Indiscernible] well business. strong [Indiscernible] our sales poultry of market lower-cost of delivered operational further driven generic and to feed COVID-XX Sales the growth which cattle pre also current period fall performed were growth pain operationally marked for comparative was our as poultry the continue expansion. X% investments quarter Overall, horse products The companion vaccines, bench across another livestock alternatives left competition and racing the quarter growth offset our cattle on delivered return cattle in as in our to all BMD, to U.S. segment primarily in quarter, offset declined U.S. remains in DRAXXIN impacted in very earlier portfolio premium technology, the was Abaxis Swine the Zoetis, XX% Zoamix component the in and alternatives decline infective of in the as decline growth essentially U.S., quarter the fish. pressure the - levels expand on in and businesses quarter and well competition, as vaccine as generic the solutions pricing was flat anti as our Diagnostics in as result portfolio to a sides key in U.S. strategic from in generic
the let's second growth XX%, Sales revenue consecutive declined $X products lifestyle X%. U.S. animal exceeded the quarter, of discuss by quarter. revenue billion XX%. grew product sales with segment of the quarterly companion for and by Now, growth for revenue
growth grew to above Petcare again revenue robust. of visits historical from patient animal, the which levels. rates be companion third were year, trends against well For Vet continued this quarter quarter clinic last and
and unchanged was remains dermatology levels. we but products. with key companion moderate, remain perform sales $XXX of Simparica our led continues by -pandemic pre year-to-date U.S. certain animal will view sales million. of to $XXX our Our Growth million in and portfolio parasiticides trends north well, U.S. that Trio above
I to excellent broader as heartworm an a for growing This Cytopoint. commitment Apoquel the as in growth in targeted the U.S. geographies. also quarter earlier quarter, very diagnostic X% parasiticide for quarter, and Key sales U.S. portfolio the with XX% for and significant sales the mentioned in the period. grew our invest pro-heart difficult were we is comparative representation launched DTC had $XXX which prevalent campaign dermatology of million
sales livestock However, the year-to-date growth. quarter. XX% performance been has in U.S. strong at XX% declined
benefited the U.S. of and a demand quarter pent-up business third for XXXX cattle the run early that's Our way through an system. its faced performance work period at growth cattle robust from comparative
the In third not addition, generic had in competition market XXXX. the entered of quarter
have generic defense has the share strategy we as Our total market expected. maintain able than to been greater been of [Indiscernible] a originally successful volume
remains efficacious resulted to challenged U.S. declined From usage quarters. likely market flocks poultry the additional as allowing pressure, producer smaller perspective, coming quarter highly the through costs, our input labor. enter market products. feed alternatives by premium Although in lower producers in lower-cost of generics and an will in the disease sales profitability end expand primarily
pricing markets, our robust addition, To with companion U.S. pressure Zoamix another innovative pet and quarter In strong operations franchises. summarize, generic and competition is our animal our care delivered creating along driven products U.S. offset been strong on NBNT near-term and by the The demonstrate displaying of by which than weakness expected strengthened very our fundamentals. more livestock been has business companion diversification across species. in has the importance animal,
made owners, and segment revenue XXXX, quarter of care our on internationally quarter, excess trend and We segment. the animal growing through market Through operationally. the X% of in quarters we saw achieved our quarter animal grew advertising year. drive a sales third continued Now, in international International revenue promotion turning favorable XX% the sales capitalize the strong operational pet livestock on XXXX, of with of of are second year. to material investments in entire this a by prior conditions entered growth. medicalization has by In in rates to dermatology of half X products. broad-based significant performance companion uptick year-to-date and XX%, standard in of Revenue key led which Companion our and growing total the growth
quarter extremely the addition, which Simparica for for Brazil, led drove and which in Eastern and on In in a life a in expect demand of in patients from Europe, Librela the quality in million markets. veterinarians stages key benefited in are additional alleviation extremely a pain antibody significant owners the we number products. by monoclonal create DTC will has [Indiscernible] and DTC growth done Feedback generating campaign quarterly pet Latin select for [Indiscernible] America. had for our campaigns has encouraging. franchise, of we been from [Indiscernible] improvement strong our dermatology, early $XX of dogs, sales growth of the internationally, well,
Our Solensia feedback and alleviation product, is global in programs overtime. need monoclone will EU becoming quarter. early the Solensia, approximately positive launched health [Indiscernible] for view antibody a a $XXX category significant experience that feline our in for blockbuster [Indiscernible] become is with and unmet cats of had animal pain the from in pain the market this QX million a
growth in revenue. instrument markets. the in with international as significant the of various China, portfolio across geographies grew diagnostics number operationally a Our UK, XX% Australia, such quarter, growth and and consumable And strong other
our cattle other growth Moving all in onto led livestock, international across growth further business favorable species, conditions operational was by fish. Cattle in and in account penetration emerging market in quarter export again delivered by Brazil, several key and growth the strong driven markets.
emerging by strong of also fueled lice was accounts, very fish well, our overall swine our poultry perform XX% as result were level a flat for exception view with in was major XX% operational QX. an market to international key markets. again a Emerging essentially operational the all markets quarter international was was which growth, basis. the well growth as Growth growing Our continues portfolio of operationally. fish to in and At well Flux segment, markets primarily the in in in sea grew Brazil, product, as contributor third as France, Alpha vaccines. increased growth by Performance portfolio of sales led market performance, key on our in primarily which treatment
as pork profitability. expected, China growth we lower third in with slowed this the in quarter challenged or As prices
a grown However, offset grew both the total markets Animal quarter weakness once swine. significantly and the in business emerging basis. in the Companion which double-digits on year-to-date in China, Overall, has again,
of livestock. grown a again On our has double-digits. growing basis, across growth segment in Companion delivered operationally our all robust Animal international growth in businesses, Companion strong Our with and year-to-date species and Animal results XX% international segment livestock each
of is prices species the the the While following across geography. our swine, importance across that in are than China pork markets it demonstrating growth offset species headwind by for diversity is creating a more moderating other growth in and and
rest favorable XX.X% for and as increased year margin basis to to P&L. inventory reported by the moving mix were compared [Indiscernible] and points prior product the price basis Adjusted on from exchange, gross low with on costs, an costs. as of XX% of charges the Now freight, a Adjusted manufacturing higher costs, increased expenses increased increased as promotion partially compensation-related freight T&E. operationally, expense, distribution resulting growing XX% and offset expenses advertising operationally operating well XXX and
of favorable for mix Our project basis [Indiscernible] tax was effective earnings to in tax expenses rate for increase a decrease net diluted XX% The to an XX.X%, changes the adjusted quarter. the income grew including foreign items to and rate. XX% growth, a margin third prior the operationally were effective jurisdictional higher increased EPS and the derived driven due gross and and lower by expansion, Adjusted comparable by discrete points to of favorability driven favorable quarter, primarily income, tangible revenue year's compared spend. related XXX adjusted quarter operationally
position liquidity equivalents healthy. were repayment and long-term cash $XXX following in in $X.X August. cash of remains the Our a in quarter billion third And very million debt
flexibilities meaningful financial repurchase $XXX by demonstrated million us position, Zoetis investments the our in a to shares returning to in which allows of make of very quarter. as in business approximately excess our Our cash shareholders, while strong
our through third rates our XXXX that Please of deliver a as a ability of sustainable quarter narrowing exchange in guidance Now, our for the updated raising reflects note and growth. our as result on and moving performance guidance future to to confidence mid-October. foreign in
and billion represents as diluted spend expected August projected promotion compensation-related income and net of operational XX%. $X.X year in for range in our to is to billion billion support in compared operational to versus reported to be raising costs, now our versus to between XX.X% our $X.XX the to between the full-year is to growth $X.XX prior and XX% billion and billion XX.X% guidance billion of range XX.X% are expected $X.XX advertising to XX.X% of be $X.X guidance Adjusted narrowing guidance franchises. increased we EPS rate XX% of to billion diluted $X.XX, as and well new $X.XX. range expected revenue products the prior XX% representing our revenue, the and guidance. $X.XXX revenue and are Adjusted the for EPS with billion, be growth of $X.XX expense and.$X.XX For now additional $X.XX The range $X.XX and now largely SG&A Adjusted guidance. the growth to key in and of be to between in
to Now, summarize, move strong again, quarters, growth our bottom-line delivered with raised XX% and full-year operationally. before we to top Q&A. narrowed operational Three guidance. XXXX And we've revenue and growing
We and new significant product extremely launches, our and our key across have growth are product achieved franchises about excited pipeline.
hand questions. for Operator. things open our operator line to over I to the your Now,
